(Press-News.org) The Gabriella Miller Kids First Pediatric Research Program (Kids First) has released its 36th study and introduced significant new data updates to two existing studies, further advancing efforts to uncover the genetic foundations of childhood cancers and congenital conditions. This brings the total data files available at the Kids First Data Resource Center (Kids First DRC) to more than 110,000.
WHO: Kids First, a program from the National Institutes of Health (NIH)
WHAT: Announcing the latest data releases to the Kids First data ecosystem. Newly released and updated datasets are available publicly, including:
CONGENITAL CONDITIONS
Kids First: Whole Genome Sequencing Studies of Multiplex Nonsyndromic Cleft Lip/Palate Families (KF-MNC)
Apply via dbGaP: phs002626
Principal Investigator: Ariadne M. Letra, PhD, University of Pittsburgh
This new study, Kids First’s 36th, explores nonsyndromic cleft lip/palate, a condition that accounts for 65% of all congenital anomalies. Short-read whole-genome sequencing (WGS) data from 828 participants in 168 multigenerational families are now available.
Kids First: Congenital Diaphragmatic Hernia (KF-CDH)
Apply via dbGaP: phs001110
Principal Investigator: Wendy Chung, MD, PhD, Columbia University Medical Center
This longstanding study received a major data update: over 1,600 new participants, 2,100 samples, and additional modalities including RNA-Seq and PacBio long-read sequencing. Congenital diaphragmatic hernia is one of the most common and lethal congenital anomalies, affecting 1 in 3,000 live births.
CHILDHOOD CANCERS
Kids First: T-cell Acute Lymphoblastic Leukemia (KF-TALL)
Apply via dbGaP: phs002276
Principal Investigator: David T. Teachey, MD, Children’s Hospital of Philadelphia
A small update adds 2 new RNA-Seq samples. This study seeks to improve risk stratification and identify genetic drivers of relapse and treatment toxicity in pediatric T-ALL.
WHEN: All datasets are available now.
WHERE: Access and explore these new data through the Kids First Data Resource Portal. Instructions for requesting access to controlled data are available in the Kids First Help Center.
WHY: By releasing high-quality genomic data from children and families affected by pediatric cancers and congenital conditions, Kids First empowers researchers everywhere to uncover new diagnostic markers, therapeutic targets, and disease risk factors. This publicly available resource promotes data sharing and collaborative discovery that could lead to life-changing treatments for children.
About the Gabriella Miller Kids First Data Resource Center (Kids First DRC)
Kids First DRC, part of the NIH Common Fund Gabriella Miller Kids First Pediatric Research Program, is a centralized, open-access, cloud-based platform that enables pediatric researchers to study the genetic links between childhood cancers and congenital conditions. It supports a global community of scientists, clinicians, and patient families working together to accelerate cures for children. Learn more at kidsfirstdrc.org.
Press Contact
Whitney Rife
rifew@chop.edu
END
New study and major data updates expand the Kids First data ecosystem
The Gabriella Miller Kids First Pediatric Research Program has released its 36th study and introduced significant new data updates to two existing studies, further advancing efforts to uncover the genetic foundations of childhood cancer
2025-09-08
ELSE PRESS RELEASES FROM THIS DATE:
Seaweed snare: Sargassum stops sea turtle hatchlings in their tracks
2025-09-08
Every year, sea turtles hatch on Florida’s beaches and make their way from the sand to the ocean – a critical journey that determines their chances of survival. As these hatchlings navigate obstacles such as artificial lights, beach debris and predators like birds and crabs, a new hazard looms. Sargassum seaweed washing up on Florida’s shores in record amounts is more than just a nuisance for beachgoers – it’s becoming a serious threat to vulnerable sea turtle hatchlings.
While it’s long been known that obstacles on the beach can slow down hatchlings and put ...
Scientists uncover key to decoupling economic growth from pollution in developing countries
2025-09-08
Balancing environmental conservation with economic progress is one of the most pressing challenges of our time. This is particularly difficult for many developing countries, which urgently need to lift their populations out of poverty while grappling with the increasing degradation of their environment. Unfortunately, a common belief is that these nations have to choose between economic growth and a clean environment—a situation made more complex by their reliance on foreign aid.
While the United Nations Sustainable Development Goals provide a global roadmap for tackling such issues, ...
Frailty fuels gut imbalance and post-surgery gastrointestinal risks
2025-09-08
Gastrointestinal (GI) complications, such as postoperative ileus (POI) and intra-abdominal infections (IAI), remain a major concern after radical cystectomy for bladder cancer. Even with advances in surgical techniques, including robot-assisted radical cystectomy with intracorporeal urinary diversion (iRARC), and the adoption of enhanced recovery protocols, these complications continue to affect a substantial proportion of patients. They not only prolong hospital stays but also increase patient morbidity, underscoring the need to identify risk factors beyond surgical technique alone.
In a new study ...
BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors
2025-09-08
Barcelona, Spain (September 8, 2025, Noon CEST / UTC +2 ) — BMS-986504, a first-in-class methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) targeting agent, showed promising antitumor activity in heavily pretreated patients with MTAP-deleted non-small cell lung cancer (NSCLC), according to results from the Phase 1CA240-0007 trial presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).
MTAP, encoding the enzyme methylthioadenosine phosphorylase, is ...
Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC
2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) ) — A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC).
The results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).
In hypofractionated ...
Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds
2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) Older individuals between the ages of 75 and 80 who are eligible for lung surgery may achieve survival outcomes comparable to younger patients following lung cancer screening, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).
Despite half of lung cancers being diagnosed in people aged 75 or older, randomized evidence on screening outcomes in this age group is limited. Most national lung cancer screening programs, including the UK’s, stop at age 74. The U.S. Preventive ...
Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy
2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) – Patients who underwent video-assisted thoracoscopic surgery (VATS) compared to open lobectomy had a significantly improved overall survival rate, according to a meta-analysis presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).
Video-assisted thoracoscopic surgery (VATS) is currently the most common approach to perform pulmonary lobectomy in early-stage lung cancer. Advantages include reduced pain, fewer complications, faster recovery and improved quality-of-life. The adoption of VATS lobectomy ...
NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC
2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) – Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.
Despite complete surgical resection (R0), early-stage NSCLC carries a substantial risk of recurrence and remains a leading cause of cancer-related ...
EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC
2025-09-08
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) — Treating patients who have stage III non-small cell lung cancer (NSCLC) with durvalumab concurrent with chemoradiotherapy (CRT) and continuing as consolidation therapy did not improve overall survival compared to consolidation durvalumab alone, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).
Consolidation durvalumab improves survival ...
Training to improve memory
2025-09-08
In Europe, almost one in 10 people over 70 suffers from dementia, and this figure could even triple by 2050 due to rising life expectancy. Over time, those affected lose everything that makes them who they are, including their memory and their ability to go about their everyday lives. Many also suffer from physical deterioration. In an advanced stage of the disorder, dementia patients generally require comprehensive care.
Now, the first drugs have emerged that can slightly slow down disease progression in the early stages of Alzheimer’s – ...
LAST 30 PRESS RELEASES:
Blood test could streamline early Alzheimer's detection
New and simple detection method for nanoplastics.
Young children are not the main drivers of language change
Tarlatamab with anti-PD-L1 as first-line maintenance after chemo-immunotherapy for ES-SCLC demonstrates acceptable safety profile and unprecedented overall survival
GLP-1 RAs and cardiovascular and kidney outcomes by body mass index in type 2 diabetes
Ambient air pollution and the severity of Alzheimer disease neuropathology
Ocean warming puts vital marine microbe Prochlorococcus at risk
Nicotine pouches may offer path to reduced tobacco harm, Rutgers study finds
Duke-NUS study reveals how dengue rewires the immune system, reshaping vaccine response
Dr. Gianluca Ianiro wins a prestigious grant from the European Research Council (ERC)
‘Rogue’ DNA rings reveal earliest clues to deadly brain cancer’s growth
Clinical study deepens understanding of mesothelioma and opens the door to potential treatment options
New study and major data updates expand the Kids First data ecosystem
Seaweed snare: Sargassum stops sea turtle hatchlings in their tracks
Scientists uncover key to decoupling economic growth from pollution in developing countries
Frailty fuels gut imbalance and post-surgery gastrointestinal risks
BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors
Phase III trial finds hypofractionated radiotherapy with chemotherapy offers comparable survival and lower toxicity to conventional schedule in LS-SCLC
Lung cancer screening benefits adults up to age 80 if surgical candidates, UK study finds
Video assisted thoracoscopy surgery reduces mortality by 21 percent compared to lobectomy
NADIM ADJUVANT trial suggests benefit of adjuvant chemo-immunotherapy in resected stage IB–IIIA NSCLC
EA5181 phase 3 trial finds no OS benefit for concurrent and consolidative durvalumab vs consolidation alone in unresectable stage 3 NSCLC
Training to improve memory
Are patients undergoing surgery for early-stage cancer at risk of persistent opioid use?
Black youth, especially Black girls, use mental health services less than their White peers
Canada must protect youth from sports betting advertising
First-in-human trial shows promising results for DLL3-targeted antibody-drug conjugate SHR-4849 in relapsed small cell lung cancer
Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer: Phase 2 IDeate-Lung01 trial
Higher blood pressure in childhood linked to earlier death from heart disease in adulthood
AI helped older adults report accurate blood pressure readings at home
[Press-News.org] New study and major data updates expand the Kids First data ecosystemThe Gabriella Miller Kids First Pediatric Research Program has released its 36th study and introduced significant new data updates to two existing studies, further advancing efforts to uncover the genetic foundations of childhood cancer